Successful therapy of a documented IFI infrequently exceeds 20%.10,115 Outcome is heavily influenced by the state of the underlying disease and recovery of neutrophils; patients with persistent granulocytopenia and unremitting underlying disease will not survive an IFI.
Development of successful antifungal agents has proved more problematic than the development of antibacterial drugs. The eukaryotic fungal cell shows a remarkable resemblance to its human counterpart and this accounts, at least in part, for the fact that many agents which exhibit excellent antifungal activity also cause unacceptable toxicity.116
Course Number: V035D
This CME Expires on July 1, 2005; no tests will be accepted after this date.
This course is accredited by
The University of Pittsburgh School of Medicine, Center for Continuing Education and The International Immunocompromised Host Society
|
